Review of Knight Therapeutics

AUG 27, 2020 - After a lengthy waiting period for investors, GUD finally closed a large deal in the last quarter of 2019, albeit in a non-traditional way. For patient investors, the potential growth remains while holding a company that provides stability through a large cash position. Rating maintained at ‘B+’.

Download Report

Knight Therapeutics Inc. (GUD)

Q: GUD seems awfully cheap at $5.05. Would you have any issues averaging down at this price? I see there was some insider buying fairly recently in the 5.25-5.30 range.

Read Answer Asked by Edward on July 29, 2021

Knight Therapeutics Inc. (GUD)

Q: Hi Team,
I still holding 1400 shares of GUD at a loss in my RIF account. Would GUD have any chance to go back up to say $6.30 ? or should I just get rid of it ?
Thank you for your assistance.
Appreciate as usual,
Tak

Read Answer Asked by Tak on July 08, 2021

Q: Gud,martello,mission ready.
Companies that have been very disappointing.
What are your thoughts ,is there any hope or cut the losses.

Read Answer Asked by Josh on June 30, 2021